Diabetes Care:hs-CRP可预测糖尿病肾病发生风险(DDCRT7注册研究)

2014-09-08 MedSci编译 MedSci原创

一项来自日本研究观察到血清超敏C反应蛋白(hs-CRP)与糖尿病肾病发生发展风险之间的关系。这项研究由Yasuaki Hayashino教授及其团队进行,属于日本糖尿病登记中心的注册研究--Diabetes Distress and Care Registry at Tenri Study(DDCRT7)。研究结果2014年08月28日的Diabetes Care杂志上,这是一项前瞻性队列研究。本

一项来自日本研究观察到血清超敏C反应蛋白(hs-CRP)与糖尿病肾病发生发展风险之间的关系。这项研究由Yasuaki Hayashino教授及其团队进行,属于日本糖尿病登记中心的注册研究--Diabetes Distress and Care Registry at Tenri Study(DDCRT7)。研究结果2014年08月28日的Diabetes Care杂志上,这是一项前瞻性队列研究。


本研究共分析了2518例2型糖尿病患者的纵向队列数据。利用Cox比例风险模型,并校正潜在混杂因素后,评估基线血清hs-CRP水平与患者1年后糖尿病肾病发生或发展之间的独立相关性。

本研究患者平均年龄为66.1岁,平均BMI为24.6kg/m2,平均HbA1c水平位7.5%。Hayashino教授发现,2型糖尿病患者基线血清hs-CRP水平与基线尿白蛋白/肌酐比值显著相关。血清hs-CRP水平位于第二四分位、第三四分位和第四四分位患者,从正常白蛋白尿进展至微量白蛋白尿的多元校正风险比分别为1.31 (95% CI 0.80–2.17; P = 0.286), 1.55 (1.16–2.08; P = 0.003), 1.57 (1.22–2.03; P = 0.001),提示血清hs-CRP水平与糖尿病肾病发生风险间呈线性相关(P < 0.001)。不过,本研究未发现hs-CRP水平与糖尿病肾病进展风险之间有明显相关性 (P for trend = 0.575)

该研究提示,2型糖尿病患者血清hs-CRP水平与糖尿病肾病发生风险相关,但与糖尿病肾病进展风险的关系没有发现。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
    2015-06-28 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
    2015-04-11 x35042875

    糖尿病肾病进展风险的关系没有发现。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
    2015-04-11 x35042875

    控制好糖尿病可能提高肝硬化患者的预后。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
    2014-09-10 rebeccajiejie
  8. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
    2014-09-10 lishiwen
  10. [GetPortalCommentsPageByObjectIdResponse(id=1759491, encodeId=9b091e594915b, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sun Jun 28 01:31:00 CST 2015, time=2015-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901245, encodeId=4ef8190124536, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Dec 13 09:31:00 CST 2014, time=2014-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20608, encodeId=366f20608c1, content=糖尿病肾病进展风险的关系没有发现。, beContent=null, objectType=article, channel=null, level=null, likeNumber=182, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:20:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=20607, encodeId=3bf32060e2d, content=控制好糖尿病可能提高肝硬化患者的预后。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20150920/IMG55FDE671A89482379.jpg, createdBy=cef3108336, createdName=x35042875, createdTime=Sat Apr 11 23:15:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636940, encodeId=bc43163694024, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Dec 19 09:31:00 CST 2014, time=2014-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764748, encodeId=f3b01e647482c, content=<a href='/topic/show?id=c73964968de' target=_blank style='color:#2F92EE;'>#注册研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64968, encryptionId=c73964968de, topicName=注册研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=510b37798730, createdName=dlwang_26703139, createdTime=Wed Aug 05 05:31:00 CST 2015, time=2015-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269574, encodeId=b0da12695e4d2, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341465, encodeId=6e321341465e8, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1552259, encodeId=79af1552259fb, content=<a href='/topic/show?id=4744913027' target=_blank style='color:#2F92EE;'>#hs-CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9130, encryptionId=4744913027, topicName=hs-CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=030314283135, createdName=lishiwen, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556710, encodeId=0b471556e10e8, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Wed Sep 10 02:31:00 CST 2014, time=2014-09-10, status=1, ipAttribution=)]
    2014-09-10 zhyy93

相关资讯

腹膜透析在终末期糖尿病肾病治疗中的应用

随着生活方式的改变,糖尿病的患病率在全世界范围内呈上升趋势。Yang等报道的中国糖尿病流行病学调查,20岁以上成人的糖尿病患病率达9.7%,而糖尿病前期的患病率高达15.5%,由此估计目前中国约9 200万糖尿病患者,1.48亿糖尿病前期患者。 而糖尿病肾病(DN)作为导致终末期肾病(ESRD)的主要病因之一,约占ESRD 20%~40%。2012年,美国。肾脏病数据库系统(USRDS)报告

Diabetologia:中山大学余学清发现糖尿病视网膜病变或可用于预测糖尿病肾病

为明确糖尿病视网膜病变在区分非糖尿病肾病与糖尿病肾病中的预测价值,来自中山大学附属第一医院的余学清教授及其团队进行了一项研究(Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis),该研究发现,在2型糖尿病

糖尿病肾病发病机制研究进展

在糖尿病人群中糖尿病肾病(DN)发病率约为20%~40%,是糖尿病的主要并发症和死亡原因。近年来随着糖尿病患者人数的快速增长,DN 的发病率逐年上升,在一些国家或地区已经成为终末期肾病(ESRD)的首位原因。DN早期主要的病理改变为肾小球肥大,肾小球和肾小管基底膜的增厚及系膜区细胞外基质(ECM)的进行性聚积;后期是肾小球、肾小管间质纤维化,最终导致蛋白尿和肾衰竭。DN 的发病机制复杂,其确切

J Am Soc Nephrol:足细胞B7-1是糖尿病肾病和蛋白尿治疗新靶点

    B7-1/CD80可能在糖尿病肾病的肾足细胞损伤中起关键性作用,文章发表在J Am Soc Nephrol上。   另外,2013年11月8日,《新英格医学杂志》在线发表的研究证实:在正常人肾脏足细胞中无表达的B7-1,可在蛋白尿动物模型的足细胞中被诱导表达;在21例有蛋白尿的肾病患者(包括FSGS)中,13例的肾活检标本足细胞有B7-1表达;采用阿巴西普治疗

Diabetes Care:血清胆红素水平或与糖尿病肾病进展有关

为了评价2型糖尿病患者血清胆红素水平与糖尿病肾病发生和发展的关系。来自日本Tenri研究小组糖尿病危害和护理登记的Mashitani博士等人进行了一项研究,研究发现,2型糖尿病患者血清胆红素水平与糖尿病肾病进展有关,且独立于可能的混杂因素。研究结果在线发表于2013年9月5日的美国《糖尿病治疗》(Diabetes Care)杂志上。【原文下载】 研究的纵向数据来自2,511名在日本糖尿病登记注册

Diabetes Care:阻塞性睡眠呼吸暂停应警惕糖尿病肾病

DiabetesCare 2013年9月23日在线版发布了英国伯明翰大学AbdA.Tahrani等开展的一项队列研究,研究显示,伴阻塞性睡眠呼吸暂停(OSA)的2型糖尿病患者发生肾病的风险是无糖尿病者的2.64倍。 在该研究中,糖尿病肾病(DN)定义为:出现白蛋白尿或估算肾小球滤过率(eGFR)<60ml/min/1.73m2;OSA定义为:呼吸暂停低通气指数(AHI)≥5次/h。在纳入研